Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients

Chemotherapy

Volumn 52, Issue 4, 2006, Pages 185-189

  Chernobelski, Pnina ^a   Lavrenkov, Konstantin ^a   Rimar, Doron ^a   Riesenberg, Klaris ^a   Schlaeffer, Francisc ^a   Ariad, Samuel ^a   Mermershtain, Wilmosh ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Ceftazidime; Cytotoxic chemotherapy; Febrile neutropenia

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAZIDIME; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BACTEREMIA; BLOOD CULTURE; CANCER; CELL COUNT; CLINICAL ARTICLE; DISEASE DURATION; FEBRILE NEUTROPENIA; FEVER; HOSPITALIZATION; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; SEPTIC SHOCK; SKIN ALLERGY; SOLID TUMOR;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CEFTAZIDIME; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745068785     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093036     Document Type: Article

References (24)

1. Schimpff S, Satterlee W, Young VM, Serpick A: Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284: 1061-1065.
2. Schimpff SC, Landesman S, Hahn DM, et al: Ticarcillin in combination with cephalothin or gentamicin as empiric antibiotic therapy in granulocytopenic cancer patients. Antimicrob Agents Chemother 1976;10:837-844.
3. Pizzo PA, Hathorn JW, Hiemenz J, et al: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-558.
4. de Pauw BE, Kauw F, Muytjens H, et al: Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother 1983;12(suppl A):93-99.
5. De Pauw BE, Deresinski SC, Feld R, et al: Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994;120:834-844.
6. Sanders JW, Powe NR, Moore RD: Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991;164:907-916.
7. Hughes WT, Armstrong D, Bodey GP, et al: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997;25:551-573.
8. Ramphal R: Is monotherapy for febrile neutropenia still a viable alternative? Clin Infect Dis 1999;29:508-514.
9. Zinner SH: Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-494.
10. Zinner SH: New pathogens in neutropenic patients with cancer: an update for the new millennium. Int J Antimicrob Agents 2000;16: 97-101.
11. Johnson MP, Ramphal R: Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990;162:981-983.
12. Kern WV: Epidemiology of fluoroquinolone-resistant Escherichia coli among neutropenic patients. Clin Infect Dis 1998;27:235-237.
13. Marron A, Carratala J, Gonzalez-Barca E, et al: Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 2000;31: 1126-1130.
14. Marron A, Carratala J, Ayats J, et al: Bacteremia due to vancomycin-resistant enterococci in neutropenic cancer patients. Med Clin (Barc) 1998;111:761-764.
15. Carratala J, Fernandez-Sevilla A, Tubau F, et al: Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-563.
16. Ariffin H, Navaratnam P, Mohamed M, et al: Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis 2000;4:21-25.
17. Marron A, Carratala J, Alcaide F, et al: High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J Antimicrob Chemother 2001;47:87-91.
18. Shenep JL: Viridans-group streptococcal infections in immunocompromised hosts. Int J Antimicrob Agents 2000;14:129-135.
19. Rolston KV, Berkey P, Bodey GP, et al: A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152:283-291.
20. Lindblad R, Rodjer S, Adriansson M, et al: Empiric monotherapy for febrile neutropenia - A randomized study comparing meropenem with ceftazidime. Scand J Infect Dis 1998;30: 237-243.
21. De Pauw BE, Raemaekers JM, Schattenberg T, Donnelly JP: Empirical and subsequent use of antibacterial agents in the febrile neutropenic patient. J Intern Med Suppl 1997;740:69-77.
22. Feld R, DePauw B, Berman S, et al: Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000;18:3690-3698.
23. Freifeld A, Marchigiani D, Walsh T, et al: A double-blind comparison of empirical oral and intravenous antibiotic therapy for low risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-311.
24. Esclavante CP, Weiser MA, Manzullo E, et al: Outcomes of treatment pathways in outpatient treatment of low risk neutropenic cancer patients. Support Care Cancer 2004;12:657-672.